ArticleDementia & neuropsychologia2025
Quantifying metabolic decrement in brain FDG-PET of a complex frontotemporal dementia case.
Article in Dementia & neuropsychologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of behavioral variant frontotemporal dementia (bvFTD) in its initial stages can be supported by brain [18F] fluorodeoxyglucose-positron emission tomography (FDG-PET). The routine use of semi-quantitative analyses in FDG-PET is formally recommended. However, the longitudinal changes observed in sequential FDG-PETs scans throughout neurodegenerative diseases remain insufficiently understood. In this case, a bvFTD phenocopy remained clinically stable for nine years before exhibiting functional decline consistent with bvFTD. Hypometabolism compatible with bvFTD was observed only on the third FDG-PET, performed six years after the first. Retrospective analysis revealed that the second FDG-PET had already shown a decline in metabolism in areas typically affected by bvFTD compared to the first scan. During the period of clinical stability, individual exams were insufficient to confirm the diagnosis. However, the metabolic decrease between the first and second scans may have indicated subclinical progression. The decline in semi-quantitative FDG-PET scores could represent a useful diagnostic tool in bvFTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.